Estraderm MX

How to order Estraderm MX

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Estraderm MX on Prescriptsy

Estraderm MX is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Estraderm MX is a transdermal patch that delivers estradiol (oestradiol), the primary natural oestrogen produced by the ovaries, through the skin into the bloodstream.

It is prescribed as hormone replacement therapy (HRT) to relieve symptoms of the menopause, including hot flushes, night sweats, vaginal dryness, sleep disturbance, mood changes and urinary symptoms caused by oestrogen deficiency.

Estraderm MX is available in four strengths: 25, 50, 75 and 100 micrograms per 24 hours.

It is a matrix-type patch applied twice weekly and is manufactured by Novartis. Estraderm MX is a prescription-only medicine (POM) in the United Kingdom.

The menopause is a natural biological event marking the end of a woman's reproductive years, defined as the permanent cessation of menstruation due to loss of ovarian follicular activity.

In the UK, the average age of menopause is 51, but it can occur earlier (premature ovarian insufficiency is defined as menopause before age 40).

During the perimenopause (the transition period before menopause) and beyond, declining oestrogen levels cause a range of symptoms that can significantly impair quality of life, work productivity, relationships and mental health.

Approximately 75 to 80% of menopausal women experience vasomotor symptoms, and for many, these symptoms persist for 7 years or more.

HRT remains the most effective treatment for menopausal vasomotor symptoms and is also beneficial for urogenital atrophy and bone protection.

This page provides a comprehensive clinical overview of Estraderm MX, including how it works, who it is suitable for, how to use it, expected benefits, potential risks, important safety information and how to obtain a prescription in the United Kingdom.

Important safety information about Estraderm MX

Before reading further, note the following essential safety points.

• Estraderm MX is a prescription-only medicine and must be used under medical supervision.
• Women with an intact uterus must take a progestogen alongside Estraderm MX to protect the endometrium.
• Do not use Estraderm MX if you have a known or suspected breast cancer, oestrogen-dependent cancer, undiagnosed vaginal bleeding, active VTE, or active liver disease.
• Seek urgent medical advice if you develop sudden chest pain, breathlessness, leg swelling, severe headache or visual disturbance.
• HRT should be reviewed at least annually with your prescriber.

Understanding the menopause and oestrogen deficiency

Oestrogen is essential for the function and health of multiple body systems.

In premenopausal women, estradiol is produced in a cyclical pattern by the ovarian follicles, regulated by the hypothalamic-pituitary-ovarian axis.

Oestrogen receptors are found throughout the body, including in the brain, cardiovascular system, bones, urogenital tract, skin, and mucous membranes.

When ovarian oestrogen production declines at the menopause, the resulting deficiency can affect any of these systems.

Vasomotor symptoms (hot flushes and night sweats) are caused by oestrogen withdrawal affecting the thermoregulatory centre in the hypothalamus, narrowing the thermoneutral zone and triggering inappropriate heat-loss responses.

Urogenital atrophy (vaginal dryness, itching, dyspareunia, urinary frequency and recurrent urinary tract infections) results from thinning and loss of elasticity of the vaginal and urethral epithelium.

Bone loss accelerates after the menopause due to increased osteoclast activity in the absence of oestrogen's bone-protective effects, increasing the risk of osteoporosis and fracture.

Mood changes, cognitive difficulties, sleep disturbance and joint pains are also commonly reported during the menopausal transition.

NICE guideline NG23 (menopause: diagnosis and management) recommends that healthcare professionals should offer HRT to women with menopausal symptoms after discussing the benefits and risks.

The guideline emphasises that for the majority of women, the benefits of HRT for symptom relief outweigh the risks, particularly when started under the age of 60 or within 10 years of menopause onset.

How Estraderm MX works

Estraderm MX is a matrix-type transdermal therapeutic system.

Unlike reservoir patches (which contain liquid estradiol behind a rate-controlling membrane), matrix patches have the active ingredient dispersed within an adhesive polymer matrix.

When applied to the skin, estradiol diffuses from the matrix through the skin and into the dermal capillaries, entering the systemic circulation directly.

Transdermal delivery bypasses first-pass hepatic metabolism.

When oestrogen is taken orally, it passes through the liver before reaching the systemic circulation, stimulating the production of clotting factors (including factor VII, fibrinogen and prothrombin), SHBG, CRP and triglycerides.

These hepatic effects are associated with an increased risk of venous thromboembolism (VTE) and may adversely affect the lipid profile.

Transdermal estradiol avoids these hepatic effects, which is why it is associated with a lower VTE risk and is preferred in women with obesity, migraine, cardiovascular risk factors, or a history of VTE.

Once in the circulation, estradiol binds to oestrogen receptors (ER-alpha and ER-beta) in target tissues, restoring oestrogen-dependent functions.

This relieves vasomotor symptoms, reverses urogenital atrophy, protects bone density and may improve mood and cognitive function.

The steady-state delivery from the patch provides stable plasma estradiol levels, avoiding the peaks and troughs associated with oral dosing.

Clinical evidence and UK prescribing guidance

HRT has been studied in numerous large clinical trials and observational studies.

The evidence base confirms that systemic HRT is the most effective treatment for vasomotor symptoms, reducing hot flush frequency by approximately 75 to 90% compared with placebo.

It also effectively treats urogenital symptoms, though local vaginal oestrogen may be preferred if urogenital symptoms are the sole complaint.

NICE NG23 recommends offering HRT as a first-line treatment for vasomotor symptoms, having discussed the benefits and risks with the woman.

The guideline specifically notes that transdermal preparations are associated with a lower risk of VTE than oral preparations and should be considered for women with risk factors for blood clots.

For women under 60 or within 10 years of menopause onset, the cardiovascular risk of HRT is generally neutral or favourable.

The British Menopause Society (BMS) publishes regularly updated guidance supporting the use of HRT for symptom relief and noting the importance of individualised risk assessment.

The BMS emphasises that the risks of HRT have been historically overstated following the WHI and MWS publications, and that for most women starting HRT at an appropriate age, the benefits outweigh the risks.

The British National Formulary (BNF) lists Estraderm MX for menopausal symptoms and osteoporosis prophylaxis in women at risk of fracture who cannot take other osteoporosis treatments or who also have menopausal symptoms.

It is classified as oestrogen-only HRT and must be combined with a progestogen in women with an intact uterus.

Who is Estraderm MX suitable for?

Estraderm MX is suitable for postmenopausal women and women in the perimenopause who are experiencing troublesome menopausal symptoms.

It is particularly favoured for women who prefer transdermal delivery (to avoid daily tablets), women at increased risk of VTE (including those with BMI over 30, personal or family history of VTE, or thrombophilia), women with migraine (especially migraine with aura, where transdermal oestrogen provides more stable hormone levels), women with gastrointestinal conditions affecting oral drug absorption, and women with hypertriglyceridaemia (as oral oestrogen can raise triglycerides).

Women with premature ovarian insufficiency (menopause before age 40) are advised to take HRT at least until the natural age of menopause (around 51) to protect bone and cardiovascular health, unless there is a specific contraindication.

Transdermal HRT is a suitable option for this group.

Dosage and administration

Choose a starting dose based on the severity of symptoms. The usual starting dose for moderate vasomotor symptoms is Estraderm MX 50 (50 micrograms per 24 hours).

For mild symptoms, Estraderm MX 25 may be sufficient.

The dose can be increased to 75 or 100 micrograms if symptoms are not adequately controlled after 4 to 6 weeks, or reduced if side effects are troublesome.

Always use the lowest effective dose.

Apply one patch to clean, dry, non-irritated skin on the lower abdomen, hip or buttock. Avoid the breasts and the waistline (where clothing may dislodge the patch).

Press firmly for at least 10 seconds. Change the patch twice weekly (every 3 to 4 days).

Rotate the application site, allowing at least one week before reapplying to the same area.

If a patch falls off, apply a new one immediately and continue with the usual schedule.

If a patch change is delayed, apply a new patch as soon as possible.

Do not apply two patches at once unless this is the dose prescribed by your clinician.

Progestogen requirements

Women who have not had a hysterectomy must take a progestogen to oppose the endometrial stimulatory effect of oestrogen.

Your prescriber will recommend either sequential combined HRT (progestogen for 12 to 14 days per calendar month, suitable for perimenopausal women) or continuous combined HRT (daily progestogen, suitable for women at least 12 months postmenopausal).

Progestogen options include oral tablets (such as medroxyprogesterone acetate, norethisterone or micronised progesterone/Utrogestan), the Mirena intrauterine system (which provides local progestogenic protection), or combined patches that include both oestrogen and progestogen.

Side effects of Estraderm MX

Common side effects

Application site reactions (redness, itching, irritation under the patch) are the most commonly reported local side effects and affect approximately 10 to 20% of users.

These are usually mild and can be managed by rotating the patch site.

Breast tenderness, headache, nausea, bloating, fluid retention and mood changes are also common, particularly in the first few months of treatment, and often improve with continued use.

Breakthrough vaginal bleeding or spotting may occur, especially during the first 3 to 6 months.

If bleeding persists beyond 6 months or starts after a period of amenorrhoea, report this to your prescriber for investigation.

Serious risks

Venous thromboembolism (DVT and PE) is a recognised risk of systemic HRT, though the risk with transdermal preparations at standard doses is significantly lower than with oral oestrogen and appears to be close to baseline risk in observational studies.

Stroke risk may be slightly increased with HRT, though the absolute risk in younger postmenopausal women is very low.

Breast cancer risk is slightly increased with combined (oestrogen plus progestogen) HRT after approximately 3 to 5 years of use; with oestrogen-only HRT, the risk is lower and may be neutral for up to 7 years of use.

Ovarian cancer risk shows a small increase with HRT use of more than 5 years, though the absolute risk is very low.

When to seek urgent advice

Call 999 or attend A&E if you develop sudden chest pain, unexplained breathlessness, painful swelling in one leg, sudden severe headache, visual disturbance, or any symptom suggestive of a blood clot or stroke.

Contact your GP if you experience persistent vaginal bleeding, new breast lumps, jaundice, or persistent mood disturbance.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Do not use Estraderm MX if you have known or suspected breast cancer, known or suspected oestrogen-dependent malignancy, undiagnosed vaginal bleeding, untreated endometrial hyperplasia, active or previous VTE (unless on anticoagulation with specialist advice), active or recent arterial thromboembolic disease, known thrombophilia, active liver disease, porphyria, or hypersensitivity to any component of the patch.

Conditions requiring careful monitoring

Oestrogen therapy may worsen or reactivate endometriosis, uterine fibroids, gallstones, otosclerosis, epilepsy, migraine, asthma, hepatic haemangiomas and SLE. Women with these conditions should be monitored regularly and treatment reviewed if symptoms recur or worsen.

Annual review

All women on HRT should have at least an annual review with their prescriber.

This should include assessment of ongoing symptom benefit, discussion of any new risk factors, breast examination if clinically indicated, and confirmation that mammography screening is up to date.

The decision to continue treatment should be made jointly, weighing individual benefits against risks.

How to get Estraderm MX in the UK

Estraderm MX is a prescription-only medicine. It can be prescribed by your GP, a menopause specialist, or an authorised online prescriber following a clinical assessment.

If your GP is not confident in managing HRT, you can request referral to an NHS menopause clinic.

The NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales and Northern Ireland.

Women using HRT may benefit from an NHS prepayment certificate (PPC) if they have multiple monthly prescriptions.

Living well during the menopause

Alongside HRT, several lifestyle measures can help manage menopausal symptoms.

Regular physical activity (at least 150 minutes per week of moderate-intensity exercise) supports cardiovascular health, bone density, mood and sleep quality.

Weight-bearing exercise (walking, dancing, resistance training) is particularly important for bone health. Maintaining a healthy weight reduces the severity of hot flushes.

Cognitive behavioural therapy (CBT) has good evidence for improving quality of life, reducing anxiety and managing vasomotor symptoms.

Reducing caffeine, alcohol and spicy food may help some women with hot flushes. Layered clothing and keeping the bedroom cool can ease night sweats.

When to seek further advice

Contact your GP or menopause specialist if your symptoms are not adequately controlled after 8 to 12 weeks of treatment, if you develop new or persistent vaginal bleeding, breast changes, or any side effects that concern you.

If you experience severe or prolonged mood changes, discuss this with your GP, as additional treatment may be helpful.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Estraderm MX, Summary of Product Characteristics (EMC)
• Estradiol, British National Formulary (BNF)
• NICE NG23: Menopause: diagnosis and management
• British Menopause Society
• Menopause, NHS
• MHRA Yellow Card Scheme